Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics Stock May Struggle After As-Expected Report
08:02am, Friday, 25'th Apr 2025
Viking Therapeutics Inc. NASDAQ: VKTX reported earnings after the market closed on Apr. 23. The stock is pushing higher as investors attempt to sort out a report that delivered no real news that inves
Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Street's Pessimism
08:58am, Thursday, 24'th Apr 2025
Viking Therapeutics' VK2735, a GLP-1 candidate, has driven significant share price gains but faces stiff competition from Eli Lilly and Novo Nordisk. Viking's Q1 earnings show no revenue, increased R&
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
07:35am, Thursday, 24'th Apr 2025
VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.
Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call Transcript
07:46pm, Wednesday, 23'rd Apr 2025
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q1 2025 Results Conference Call April 23, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Ex
Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 23'rd Apr 2025
Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25 Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25 Broad Man
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
10:36am, Tuesday, 22'nd Apr 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Is Viking Therapeutics Stock (VKTX) Nearing A Bottom?
11:39pm, Monday, 21'st Apr 2025
With earnings scheduled for the 23rd, Viking Therapeutic's (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates. The spotlight will be on three clinical candi
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
06:56pm, Thursday, 17'th Apr 2025
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close.
2 Stocks Down by 25% or More This Year to Buy and Hold
10:00am, Thursday, 17'th Apr 2025
Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to look
Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)
09:30am, Thursday, 17'th Apr 2025
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improve
Viking Therapeutics Stock Pops But Struggles to Hold Gains
10:33am, Wednesday, 16'th Apr 2025
Viking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024.
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market
04:21pm, Tuesday, 15'th Apr 2025
Viking Therapeutics, Inc. stock has dropped ~35% amid market volatility, but Pfizer's withdrawal of danuglipron boosts VK2735's prospects as a leading oral GLP-1 for obesity. Goldman Sachs' Neutral ra
Will Pfizer approach Viking Therapeutics with a buyout proposal?
03:26pm, Tuesday, 15'th Apr 2025
Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed Pfizer (NYSE: PFE) into terminating the development of its weight-loss pil
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
02:37pm, Tuesday, 15'th Apr 2025
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in w
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
11:00am, Tuesday, 15'th Apr 2025
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
